Announcing the publication of ‘Fear, Religion, Politics; Well I’ll Be Darn’ by Dr. John E. Karlin, former professor of Sociology at Northwestern Oklahoma State University, Oklahoma City University and Phillips University, Enid, OK. Dr. Karlin spent over a year in research and writing this excellent work which is currently listed on amazon.com.
This book is non-fiction and written with three parts.
Part One: Entitled ‘The problem that won’t go away’, examines the relationship between the fear of death and religion. The problem that won’t go away is our own mortality and the consequences of our consciousness of it.
Part Two: Entitled ‘The dream’ examines the goal/objective that Jesus Christ’s life, words and actions indicate that he was trying to achieve during his own lifetime.
Part Three: Entitled ‘A dream gone awry’ examines the relationship between religion and politics today. That relationship has and continues to destroy any chance of that dream coming true.
All three themes are intertwined and explain the political atmosphere today.
For more details call: Dr. John Karlin at 405-598-6590.

Dear Savvy Senior, A good friend of mine got a bad case of shingles last year and has been urging me to get vaccinated. Should I? Suspicious Susan

Dear Susan,
Yes! If you’re 50 or older, there’s a new shingles vaccine on the market that’s far superior to the older vaccine, so now is a great time to get inoculated. Here’s what you should know.
Shingles, also known as herpes zoster, is a burning, blistering, often excruciating skin rash that affects around 1 million Americans each year. The same virus that causes chickenpox causes shingles. What happens is the chickenpox virus that most people get as kids never leaves the body. It hides in the nerve cells near the spinal cord and, for some people, emerges later in the form of shingles.
In the U.S., almost one out of every three people will develop shingles during their lifetime. While anyone who’s had chickenpox can get shingles, it most commonly occurs in people over age 50, along with people who have weakened immune systems. But you can’t catch shingles from someone else.
Early signs of the disease include pain, itching or tingling before a blistering rash appears several days later, and can last up to four weeks. The rash typically occurs on one side of the body, often as a band of blisters that extends from the middle of your back around to the breastbone. It can also appear above an eye or on the side of the face or neck.
In addition to the rash, about 20 to 25 percent of those who get shingles go on to develop severe nerve pain (postherpetic neuralgia, or PHN) that can last for months or even years. And in rare cases, shingles can also cause strokes, encephalitis, spinal cord damage and vision loss.
New Shingles Vaccine
The Food and Drug Administration recently approved a new vaccine for shingles called Shingrix (see Shingrix.com), which provides much better protection than the older vaccine, Zostavax.
Manufactured by GlaxoSmithKline, Shingrix is 97 percent effective in preventing shingles in people 50 to 69 years old, and 91 percent effective in those 70 and older.
By comparison, Zostavax is 70 percent effective in your 50s; 64 percent effective in your 60s; 41 percent effective in your 70s; and 18 percent effective in your 80s.
Shingrix is also better that Zostavax in preventing nerve pain that continues after a shingles rash has cleared – about 90 percent effective versus 65 percent effective.
Because of this enhanced protection, the Center for Disease Control and Prevention recommends that everyone age 50 and older, receive the Shingrix vaccine, which is given in two doses, two to six months apart.
Even if you’ve already had shingles, you still need these vaccinations because reoccurring cases are possible. The CDC also recommends that anyone previously vaccinated with Zostavax be revaccinated with Shingrix.
You should also know that Shingrix can cause some adverse side effects for some people, including muscle pain, fatigue, headache, fever and upset stomach.
Shingrix – which costs around $280 for both doses – is (or will soon be) covered by insurance including Medicare Part D prescription drug plans, but be aware that the shingles vaccines are not always well covered. So before getting vaccinated, call your plan to find out if it’s covered, and if so, which pharmacies and doctors in your area you should use to insure the best coverage.
Or, if you don’t have health insurance or you’re experiencing medical or financial hardship, you might qualify for GlaxoSmithKline’s Patient Assistance Program, which provides free vaccinations to those who are eligible. For details, go to GSKforyou.com.

Send your senior questions to: Savvy Senior, P.O. Box 5443, Norman, OK 73070, or visit SavvySenior.org. Jim Miller is a contributor to the NBC Today show and author of “The Savvy Senior” book.

Miniaturized Heart Device Provides Patients with the Most Advanced Pacing Technology Available

INTEGRIS Heart Hospital is one of the first hospitals in Oklahoma to offer the world’s smallest pacemaker for patients with bradycardia. The Micra® Transcatheter Pacing System (TPS) is a new type of heart device, approved for Medicare reimbursement, that provides patients with the most advanced pacing technology at one-tenth the size of a traditional pacemaker.
The first procedure at INTEGRIS Baptist Medical Center was performed by Terrance Khastgir, M.D., a cardiac electrophysiologist with INTEGRIS Heart Hospital, on Aug. 7, 2018.
Bradycardia is a condition characterized by a slow or irregular heart rhythm, usually fewer than 60 beats per minute. At this rate, the heart is unable to pump enough oxygen-rich blood to the body during normal activity or exercise, causing dizziness, fatigue, shortness of breath or fainting spells. Pacemakers are the most common way to treat bradycardia to help restore the heart’s normal rhythm and relieve symptoms by sending electrical impulses to the heart to increase the heart rate.
Comparable in size to a large vitamin, physicians at INTEGRIS Heart Hospital have elected to use Medtronic’s Micra TPS because unlike traditional pacemakers, the device does not require cardiac wires (leads) or a surgical “pocket” under the skin to deliver a pacing therapy. Instead, the device is small enough to be delivered through a catheter and implanted directly into the heart with small tines, providing a safe alternative to conventional pacemakers without the complications associated with leads – all while being cosmetically invisible. The Micra TPS is also designed to automatically adjust pacing therapy based on a patient’s activity levels.
“This device will allow our patients to get the most advanced technology in pacing the heart for slow heart rate,” stated Khastgir.
The Micra TPS also incorporates a retrieval feature to enable retrieval of the device when possible; however, the device is designed to be left in the body. For patients who need more than one heart device, the miniaturized Micra TPS was designed with a unique feature that enables it to be permanently turned off so it can remain in the body and a new device can be implanted without risk of electrical interaction.
The Micra TPS is the first and only transcatheter pacing system to be approved for both 1.5 and 3 Tesla (T) full-body magnetic resonance imaging (MRI) scans and is designed to allow patients to be followed by their physicians and send data remotely via the Medtronic CareLink® Network.
The Micra TPS was approved by the U.S. Food and Drug Administration in April 2016, and has been granted Medicare reimbursement, allowing broad patient access to the novel pacing technology.